Clinical outcomes | At 30 day follow-up N = 372 | At 6 month follow-up N = 372 | At 12 month follow-up N = 368 | At 24 month follow-up N = 365 |
Death from any cause, n (%) | 2 (0.5%) | 6 (1.6%) | 7 (1.9%) | 10 (2.7%) |
Cardiac death, n (%) | 2 (0.5%) | 4 (1.1%) | 5 (1.4%) | 7 (1.9%) |
Non-cardiac death, n (%) | 0 (0%) | 2 (0.5%) | 2 (0.5%) | 3 (0.8%) |
Myocardial infarction, n (%) | 2 (0.5%) | 2 (0.5%) | 3 (0.8%) | 4 (1.1%) |
Target lesion revascularization, n (%) | 0 (0%) | 2 (0.5%) | 3 (0.8%) | 3 (0.8%) |
Target vessel revascularization, n (%) | 0 (0%) | 3 (0.8%) | 4 (1.1%) | 4 (1.1%) |
Overall stent thrombosis, n (%) | 2 (0.5%) | 3 (0.8%) | 3 (0.8%) | 4 (1.1%) |
Definite stent thrombosis, n (%) | 1 (0.3%) | 1 (0.3%) | 1 (0.3%) | 1 (0.3%) |
Probable stent thrombosis, n (%) | 1 (0.3%) | 2 (0.5%) | 2 (0.5%) | 3 (0.8%) |
Possible stent thrombosis, n (%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Major adverse cardiac events, n (%) | 4 (1.1%) | 8 (2.2%) | 11 (3.0%) | 14 (3.8%) |